Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.42 |
| ▸ | RIPK3 | Q9Y572 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.36 |
| ▸ | CNOT7 | Q9UIV1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3527861 | 0.88 | MAPK14 (0.54) | PKMSMN1; SMN2MAPK14KDM4EL3MBTL1 | |
| SCHEMBL4467661 | 0.86 | MAPK14 (0.59) | MAPK14RIPK3 | |
| SCHEMBL3522063 | 0.83 | PKM (0.53) | PKMSMN1; SMN2MAPK14KDM4EL3MBTL1 | |
| SCHEMBL3527233 | 0.78 | MAPK14 (0.61) | MAPK14 | |
| SCHEMBL3522554 | 0.76 | MAPK14 (0.56) | MAPK14 | |
| SCHEMBL5268247 | 0.76 | SQOR (0.39) | MAPK14RIPK3GRIN1GRIN2BSQOR | |
| SCHEMBL3518775 | 0.76 | MAPK14 (0.69) | MAPK14 | |
| SCHEMBL3520146 | 0.74 | MAPK14 (0.55) | PKMSMN1; SMN2MAPK14KDM4E | |
| SCHEMBL6649455 | 0.73 | MAPK14 (0.37) | MAPK14RIPK3GRIN1GRIN2BSQOR | |
| SCHEMBL3522196 | 0.73 | MAPK14 (0.53) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795271-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | PFIZER INC | 2009-12-10 | — | — | US | disclosed |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | PHARMACIA CORPORATION (US) | 2007-07-19 | — | — | US | disclosed |
| US-7183287-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040242608-A1 | Substituted pyrimidinones | PHARMACIA LLC | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | PKM 994/4885SMN1; SMN2 912/4885MAPK14 38/4885 |
| US-20040242608-A1 | Substituted pyrimidinones | MAPK1, MAPK7, MAP3K8 | PKM 1090/4885SMN1; SMN2 746/4885MAPK14 29/4885 |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | PKM 994/4885SMN1; SMN2 912/4885MAPK14 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.